Insomnia News and Research RSS Feed - Insomnia News and Research

Insomnia is too little or poor-quality sleep caused by one or more of the following:

Trouble falling asleep
Waking up a lot during the night with trouble returning to sleep
Waking up too early in the morning
Having un-refreshing sleep (not feeling well rested), even after sleeping 7 to 8 hours at night

Insomnia can cause problems during the day, such as excessive sleepiness, fatigue, trouble thinking clearly or staying focused, or feeling depressed or irritable. It is not defined by the number of hours you sleep every night. Although the amount of sleep a person needs varies, most people need between 7 and 8 hours of sleep a night.
FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. [More]
Study helps explain why sleep becomes more fragmented with age

Study helps explain why sleep becomes more fragmented with age

As people grow older, they often have difficulty falling asleep and staying asleep, and tend to awaken too early in the morning. [More]
FDA approves BELSOMRA® (suvorexant) for the treatment of insomnia

FDA approves BELSOMRA® (suvorexant) for the treatment of insomnia

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA® (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA (pronounced bell-SOM-rah) is a highly selective antagonist for orexin receptors. [More]
People who suffer from MdDS now have chance for full recovery by new treatment

People who suffer from MdDS now have chance for full recovery by new treatment

People who suffer from a rare illness, the Mal de Debarquement Syndrome (MdDS), now have a chance for full recovery thanks to treatment developed by researchers at the Icahn School of Medicine at Mount Sinai. [More]
Anti-cholinergic drugs could be responsible for decline in cognitive, physical function in elderly patients

Anti-cholinergic drugs could be responsible for decline in cognitive, physical function in elderly patients

Drugs widely prescribed to the elderly could be responsible for a decline in cognitive and physical function according to research from the University of East Anglia and the Regenstrief Institute. [More]
Study shows link between insomnia-related mental health conditions among teens

Study shows link between insomnia-related mental health conditions among teens

A study of high school students by University of Adelaide psychology researchers has shed new light on the links between insomnia-related mental health conditions among teens. [More]
New data on possible protective behaviors and dementia risk factors emerges at AAIC- 2014

New data on possible protective behaviors and dementia risk factors emerges at AAIC- 2014

Participation in activities that promote mental activity, and moderate physical activity in middle age, may help protect against the development of Alzheimer's disease and dementia in later life, according to new research reported today at the Alzheimer's Association International Conference- 2014 (AAIC- 2014) in Copenhagen. [More]
CSI and Fabien Cousteau's Mission 31 examine impact of sleep in individuals living underwater

CSI and Fabien Cousteau's Mission 31 examine impact of sleep in individuals living underwater

United States Navy and NASA researchers have each examined the impact of sleep in individuals living and working underwater but researchers with Clayton Sleep Institute (CSI) in St. Louis are hoping to gain new insight with a study in cooperation with Fabien Cousteau's Mission 31. [More]
Study identifies specific coping behaviors through which stress exposure leads to insomnia

Study identifies specific coping behaviors through which stress exposure leads to insomnia

A new study is the first to identify specific coping behaviors through which stress exposure leads to the development of insomnia. [More]
ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. [More]
Good news for adults who suffer from insomnia

Good news for adults who suffer from insomnia

There's good news for the 30 per cent or more of adults who suffer from insomnia--difficulty falling asleep, waking up for prolonged periods during the night or unwanted early morning awakenings. [More]
Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Alkermes plc today announced the presentation of data from its phase 3 clinical trial of aripiprazole lauroxil, an investigational drug candidate in development for schizophrenia, at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Fla. [More]
Researchers explore shiatsu to help people with chronic pain fall asleep

Researchers explore shiatsu to help people with chronic pain fall asleep

There was a time, back in Nancy Cheyne's youth, when she combined the poise and grace of a ballerina with the daring and grit of a barrel racer. When she wasn't pursuing either of those pastimes, she bred sheepdogs, often spending hours on her feet grooming her furry friends at dog shows. [More]
Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Combining two smoking cessation therapies is more effective than using just one for male and highly nicotine-dependent smokers who weren't initially helped by the nicotine patch, according to researchers at Duke Medicine. [More]
Fighting off illness causes sleep deprivation and affects memory

Fighting off illness causes sleep deprivation and affects memory

Sickness-induced insomnia is common because of link between brain and immune system. Fighting off illness- rather than the illness itself- causes sleep deprivation and affects memory, a new study has found. [More]
Proteins causing daytime sleepiness also play crucial role in bone formation

Proteins causing daytime sleepiness also play crucial role in bone formation

Orexin proteins, which are blamed for spontaneous daytime sleepiness, also play a crucial role in bone formation, according to findings by UT Southwestern Medical Center researchers. [More]
Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV). [More]
Chronic sleep loss can cause certain neurotoxic molecules to permeate into brain tissue

Chronic sleep loss can cause certain neurotoxic molecules to permeate into brain tissue

The longer the insomnia, junctions of cerebral blood vessels begin to degrade. In search of the answer to why do we sleep, research conducted at the Mexican Metropolitan Autonomous University (UAM) revealed that chronic sleep loss can cause certain neurotoxic molecules, which normally circulate in the blood, to be transported to the central nervous system and interfere with the function of neurons. [More]
BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA). [More]
Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck, known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company's global Phase 3 clinical trial, ONCEMRK. [More]